Q1 Earnings Forecast for OptimizeRx Issued By Roth Capital

OptimizeRx Co. (NASDAQ:OPRX) – Analysts at Roth Capital issued their Q1 2026 earnings per share estimates for OptimizeRx in a report released on Wednesday, March 12th. Roth Capital analyst R. Baldry expects that the company will post earnings per share of ($0.19) for the quarter. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for OptimizeRx’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.05) EPS and Q4 2026 earnings at $0.44 EPS.

Several other brokerages have also recently issued reports on OPRX. Lake Street Capital reissued a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and issued a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. B. Riley raised OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, Stephens assumed coverage on OptimizeRx in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective on the stock. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Trading Up 9.1 %

Shares of NASDAQ:OPRX opened at $9.02 on Monday. The stock has a market capitalization of $166.16 million, a price-to-earnings ratio of -6.78 and a beta of 1.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock’s 50-day simple moving average is $5.64 and its two-hundred day simple moving average is $5.90. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $14.13.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. bought a new stake in OptimizeRx during the 4th quarter valued at approximately $25,000. BNP Paribas Financial Markets raised its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the period. SG Americas Securities LLC bought a new stake in OptimizeRx during the 4th quarter valued at approximately $51,000. Wells Fargo & Company MN raised its stake in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock valued at $54,000 after purchasing an additional 2,797 shares during the period. Finally, Quest Partners LLC raised its stake in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after purchasing an additional 9,739 shares during the period. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.